Morphine Sulfate Extended-Release Articles
King divests drug to clear Alpharma merger
12 January 2009
Alpharma relents, accepting King Pharma
1 December 2008
UPDATE: King "committed" to $1.4B bid for Alpharma, seeks to strengthen painkiller franchise
1 September 2008
Stock Commentary - New York week to Feb 11, 2008
18 February 2008
Stock Commentary - New York week to Feb 4, 2008
11 February 2008
Actavis challenges King's Avinza patent with ANDA filing
24 September 2007
King's 1st-qtr 2007 revenue increases 7%
21 May 2007
Ligand completes sale of Avinza to King
5 March 2007
FDA Approval for Alpharma's Kadian 80mg
6 November 2006
Ligand's 1st-qtr 2006 revenues up 38%
29 May 2006
Alpharma's 2nd qtr sees 16% revenue rise
15 August 2005
FDA requests label change for Ligand's Avinza
8 August 2005
Stock Commentary - New York
8 August 2005
Alpharma to change Kadian labeling
1 August 2005
Stock Commentary - New York
16 May 2005
Alpharma and Synthon to co-promote Pexeva
24 January 2005
Ligand sets up pain and oncology units
15 November 2004
MGI and Alpharma in Kadian promotion deal
19 July 2004
Ligand raises $47M in private placing
22 September 2003
R&D costs offset 140% sales rise at Ligand
18 August 2003
Faulding wins Kadian law suit in USA
15 January 2001
Faulding's Kadian OKed in Japan
28 October 1999
Interim Financial Results From The USA
18 November 1996
Strong Fundamentals On Show At Zeneca
19 August 1996
Approval For Faulding's Kadian
15 July 1996
Zeneca Licenses Faulding's Oral Morphine
4 March 1996
Faulding's Morphine Drug Covers Ground
24 July 1995
Faulding To Seek Managed Care Alliance
17 July 1995
Oral Morphine
16 January 1995
Australian Drug Firms Move Abroad
9 January 1995
Showing 1-34 of 34 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
